Overview
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are:
- Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)?
- How does treatment duration affect perioperative safety and clinical outcomes?
Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.
Eligibility
Inclusion Criteria:
- Non-bedridden patients aged 18-90 years;
- Histologically confirmed gastric or gastroesophageal junction adenocarcinoma by biopsy;
- Evaluated as resectable advanced gastric cancer via CT, MRI, or laparoscopic exploration;
- No prior anti-tumor treatments such as chemotherapy, radiotherapy, or immunotherapy;
- No history of other malignancies within the past 5 years;
- Received at least one cycle of PD-1 inhibitor combined with chemotherapy preoperatively, with no restrictions on the specific PD-1 inhibitor or chemotherapeutic agents;
- Underwent radical gastrectomy after neoadjuvant therapy;
- No severe underlying diseases.
Exclusion Criteria:
- Incomplete or inaccessible clinical and pathological data;
- Postoperative pathology confirming non-gastric or non-gastroesophageal junction adenocarcinoma;
- Distant metastases present prior to treatment;
- Concurrent diagnosis of other malignancies.